

Genetic Antagonism and Hypermutability in *Mycobacterium smegmatis*

PONNIAH KARUNAKARAN† AND JULIAN DAVIES*

Department of Microbiology and Immunology, The University of British Columbia,
Vancouver, British Columbia V6T 1Z3, Canada

Received 27 October 1999/Accepted 31 March 2000

Multidrug-resistant strains of *Mycobacterium tuberculosis* are a serious and continuing human health problem. Such strains may contain as many as four or five different mutations, and *M. tuberculosis* strains that are resistant to both streptomycin and rifampin contain mutations in the *rpsL* and *rpoB* genes, respectively. Coexisting mutations of this kind in *Escherichia coli* have been shown to interact negatively (S. L. Chakrabarti and L. Gorini, Proc. Natl. Acad. Sci. USA 72:2084–2087, 1975; S. L. Chakrabarti and L. Gorini, Proc. Natl. Acad. Sci. USA 74:1157–1161, 1977). We investigated this possibility in *Mycobacterium smegmatis* by analyzing the frequency and nature of spontaneous mutants that are resistant to either streptomycin or rifampin or to both antibiotics. Mutants resistant to streptomycin were isolated from characterized rifampin-resistant mutants of *M. smegmatis* under selection either for one or for both antibiotics. Similarly, mutants resistant to rifampin were isolated from streptomycin-resistant strains. The second antibiotic resistance mutation occurred at a lower frequency in both cases. Surprisingly, in both cases a very high rate of reversion of the initial antibiotic resistance allele was detected when single antibiotic selection was used; the majority of strains resistant to only one antibiotic were isolated by this process. Determinations of rates of mutation to antibiotic resistance in *M. smegmatis* showed that the frequencies were enhanced up to 10⁴-fold during stationary phase. If such behavior is also typical of slow-growing pathogenic mycobacteria, these studies suggest that the generation of multiply drug-resistant strains by successive mutations may be a more complex genetic phenomenon than suspected.

The rapid emergence of multidrug-resistant *Mycobacterium tuberculosis* (MDRTB) strains has renewed interest in studies of the development of antibiotic resistance in mycobacteria. Streptomycin was the first antibiotic shown to be active against *M. tuberculosis* and was responsible for the successful treatment of millions of patients (3). The drug acts on ribosomes and causes aberrant proofreading leading to misreading of the genetic code and inhibition of initiation of translation (23). Mutations associated with streptomycin resistance (Str^r) have been identified in two targets, the 16S rRNA gene (*rrs*) and the gene (*rpsL*) encoding ribosomal protein S12; both types of mutants have been characterized in *M. tuberculosis* (11). Rifampin has also been effectively employed in the treatment of tuberculosis; rifampin inhibits transcription by binding to the β -subunit of RNA polymerase (14), and rifampin-resistant (Rif^r) mutants of *M. tuberculosis* have been found to harbor mutations in the *rpoB* gene, encoding this subunit (25). The two types of mutation have been shown to be present simultaneously in many strains of MDRTB identified in recent years (16). Early studies with *Escherichia coli* by Chakrabarti and Gorini (5, 6) had shown that there is antagonism between *rpsL* and *rpoB* mutations. We have analyzed mutation to Str^r and Rif^r and the appearance of double mutants to examine whether a similar type of antagonism is manifested in *Mycobacterium smegmatis*. Such antagonism was confirmed, but in addition we noted that mutation rates increased significantly during the postexponential growth phase of *M. smegmatis*.

(This work was presented as a poster at the 99th General Meeting of the American Society for Microbiology held in Chicago, Ill., from 30 May to 3 June 1999.)

MATERIALS AND METHODS

Bacterial strains, media, and growth conditions. All Str^r and/or Rif^r mutants were isolated from the antibiotic-sensitive *M. smegmatis* mc²6. Revertants of histidine-requiring auxotrophs were isolated from *M. smegmatis* his5 (13). Cells were grown at 30°C in tryptic soy broth (TSB) medium (Difco) containing 0.5% glycerol. For solid medium, agar was added at 15 g per liter and glycerol was omitted. Revertants of *M. smegmatis* his5 were isolated by plating on 7H10 agar medium (BBL) containing 0.5% glycerol (without supplement). Viable counts were determined by plating appropriate dilutions of liquid cultures onto solid medium without antibiotic.

Isolation of spontaneous Str^r and/or Rif^r mutants. *M. smegmatis* (10⁸ CFU) was spread on plates containing 100 μ g of streptomycin/ml and/or 500 μ g of rifampin/ml. The plates were incubated at 30°C until colonies started to appear (about 3 to 5 days). The colonies were purified and their resistance characteristics were confirmed by restreaking onto agar plates containing appropriate antibiotics.

Detection of mutations in the *rpsL* and *rpoB* genes. The *rpsL* gene (GenBank accession no. L34681) was amplified by PCR with primers L1 (5'-CGG TAG ATG CCA ACC ATC CAG CA-3') and L2 (5'-CCT TGC GTG GCA TCA GCC CTT CT-3'), generating a fragment of 393 bp containing the complete gene. The *rpoB* gene (GenBank accession no. U24494) was amplified by PCR with primers B1 (5'-GGA CGT GGA GGC GAT CAC ACC-3') and B2 (5'-CGT AGC GAC CGA CAC CAT CTG-3'), generating a fragment of 553 bp containing the region from codons 482 to 666. This segment includes the so-called rifampin resistance-determining region (17). The fragments were amplified from single *M. smegmatis* colonies added to the PCR mixture with a toothpick. The reaction mixture contained 1.5 mM MgCl₂, 150 μ M deoxynucleoside triphosphates, 5 U of *Taq* polymerase enzyme, and 25 pmol of each oligonucleotide primer in a total volume of 50 μ l. The PCR cycling conditions were as follows: 1 cycle of 95°C for 5 min and 30 cycles of 94°C for 30 s, 60°C for 30 s, and 72°C for 1 min. This was followed by strand elongation for 10 min at 72°C. The PCR product was purified with the QIAquick PCR purification kit (Qiagen), and the purified DNA fragment was sequenced with dye-labeled terminators and primer (L1, L2, B1, or B2), using the AmpliTaq Prism kit (Applied Biosystems).

Nucleotide sequence analysis of the *hisD* gene. The *hisD* gene of *M. smegmatis* his5 and its revertants were PCR amplified with primers F1 (5'-GTT GAC GGT GGC CGA CGG AT-3') and R1 (5'-CTC GTT GGT GTT CAG GCG CA-3'),

* Corresponding author. Mailing address: Department of Microbiology and Immunology, The University of British Columbia, 6174 University Blvd., Vancouver, B.C. V6T 1Z3, Canada. Phone: (604) 822-8883. Fax: (604) 822-6041. E-mail: jed@unixg.ubc.ca.

† Present address: University of British Columbia Centre for Disease Control, Vancouver, British Columbia V5Z 4R4, Canada.




FIG. 1. PCR strategy used to analyze the nucleotide sequence of *hisD*. The 1,338-nucleotide *hisD* coding sequence is represented by the rectangle, and the primers used to amplify and/or sequence the gene are indicated by arrows. The codon numbering is based on *M. smegmatis hisD* sequence data published by Hinshelwood and Stoker (13).

generating a fragment of 1,499 bp containing the complete gene (Fig. 1). PCR conditions were as described above. The PCR product was sequenced with additional primers F2 (5'-ATC CGT CGA GCG TCG TGA TG-3') and F3 (5'-CCA CCA CCA AGC ACG TCG AG-3').

EASPCR. Enriched allele-specific PCR (EASPCR) was used to identify the appearance of *Str^r* mutants in liquid culture before plating on selective media (Fig. 2). EASPCR involved two steps. Step one was to generate the *rpsL* gene fragments of both the wild type and mutants (PCR I), followed by *Mbo*II restriction enzyme digestion to eliminate wild-type templates. Step two involved amplification of allele-specific product (PCR II). This was done with three primers: two non-allele-specific primers (L11 [5'-GAC AAG ATC GCC AAG GTG AAG AC-3'] and L22 [5'-TCT TCT CCT TCT TCG CGC CAT AG-3']) and one primer specific to the mutant allele (L25 [5'-CCG GAG CGC CGA GTT CGG CTA CC-3']). PCR conditions were the same as described above except that for PCR II, the annealing temperature was 63°C and the number of cycles was 25. Two products (335 and 93 bp) were generated from the template containing mutant allele and none were generated from the wild-type template.

RESULTS

Isolation of antibiotic-resistant mutants. Spontaneous mutants of *M. smegmatis* resistant to either streptomycin or rifampin were isolated (Fig. 3), and the frequencies of appearance of mutants were determined (Table 1). About 10




FIG. 2. EASPCR to identify the appearance of *rpsL* mutations in liquid culture before plating on selective media. (A) Outline of the procedure. (B) EASPCR of samples taken at different times. M, PCR marker; lane 1, negative control; lane 2, wild type; lane 3, *Str^r* mutant; lane 4, *Rif^r* mutant (3-day culture); lane 5, *Rif^r* mutant (8-day culture); lanes 6 to 9, same as lanes 2 to 5 but without *Mbo*II digestion before PCR II.




FIG. 3. Flow chart describing mutant isolation. Rif, rifampin; Str, streptomycin; *, selective medium contains the indicated drug.

independent colonies of each mutant type were selected for sequencing of the *rpsL* or *rpoB* gene in order to characterize the mutations. All *rpsL* mutants had mutations at codon 43, and Lys-to-Arg (AAG→AGG) transitions were more frequent than Lys-to-Thr (AAG→ACG) or Lys-to-Asn (AAG→AAT or AAC) transversions. All but one of the sequenced *rpsL* mutants also had a neutral base substitution (CCG→CCA) at codon 45. Mutations in *rpoB* were located at codon 526; His-to-Arg (CAC→CGC) transversions arose most frequently, followed by either His-to-Pro (CAC→CCC) or His-to-Tyr (CAC→TAC) transversions. In the second step, mutants resistant to streptomycin were isolated from chosen rifampin-resistant mutants and vice versa. During this step, antibiotic selection was made on solid media containing either one or both antibiotics. It was noted that the frequencies of appearance of the second antibiotic resistance were always low when simultaneous selection for streptomycin and rifampin resistance was made (Table 1).

In addition, it was noted that the frequencies of appearance of mutants resistant to either streptomycin or rifampin varied as a function of the phase of growth in liquid culture when *M. smegmatis* cells were plated on antibiotic selection medium (Fig. 4). When the cultures were plated in late stationary phase, frequencies of appearance of mutants resistant to antibiotics as high as 10^{-3} mutant CFU/total CFU were observed.

Analysis of streptomycin and rifampin mutations. Mutants that appeared after single (rifampin or streptomycin) and double (streptomycin and rifampin) selection were tested for re-

TABLE 1. Frequencies of the appearance of spontaneous mutants resistant to streptomycin and/or rifampin in *M. smegmatis*^a

Strain	Mutation frequency with drug	
	Str*	Rif*
Wild type <i>mc</i> ²⁶	$>2 \times 10^{-4}$	$>2.4 \times 10^{-5}$
<i>Str^r</i> mutant R43L N43L	Rif* $>4.5 \times 10^{-5}$ $>2.5 \times 10^{-5}$	Rif + Str* 9.0×10^{-7} 4.2×10^{-8}
<i>Rif^r</i> mutant R526H Y526H	Str* $>2 \times 10^{-3}$ $>4 \times 10^{-4}$	Str + Rif* 2.5×10^{-7} 5.5×10^{-8}

^a The frequencies of the appearance of resistant mutants are relative to the total CFU plated. Str, streptomycin; Rif, rifampin; *, selective medium contains the indicated drug.




FIG. 4. Growth phase-dependent hypermutability in *M. smegmatis*, shown as frequencies of the appearance of resistant mutants.

sistance to one or both antibiotics and then analyzed by sequencing the *rpsL* and *rpoB* genes. It was found that selection for streptomycin resistance in rifampin-resistant mutants was accompanied by a high-level reversion of rifampin resistance to sensitivity, and conversely, when streptomycin-resistant mutants were selected for resistance to rifampin, the streptomycin resistance phenotype was also preferentially lost. The reversion of Str^r to Str^s (*rpsL*) was identified by a change in codon 43 (Arg to Lys [AGG→AAG] or Asn to Lys [AAT→AAG]), and reversion of Rif^r to Rif^s (*rpoB*) was identified by a change in codon 526 (Arg to His [CGC→CAC] or Tyr to His [TAC→CAC]) (Table 2). It is of interest that the single base changes were reversions of the initial antibiotic resistance mutation. Similar antagonistic effects were observed during attempts to isolate double mutants resistant to streptomycin and ciprofloxacin in *M. smegmatis* (K. Lu, P. Karunakaran, and J. E. Davies, unpublished data). In companion studies, the isolation of streptomycin- and rifampin-resistant mutants of *Mycobacterium phlei* indicated that reversion of the nonse-

lected phenotype also occurred in this mycobacterial species (results not shown).

At least two of each of the double mutants resistant to rifampin and streptomycin mentioned in Table 1 were characterized by sequencing the *rpsL* and *rpoB* genes. All the mutants characterized contained mutations in both the *rpsL* and *rpoB* genes. The temperature sensitivities of these mutants were tested by plating at 30 and 42°C, and all the tested mutants grew at both temperatures.

To investigate the possibility of RecA-mediated gene conversion as a cause for high-frequency reversion, a *recA* mutant strain (HS42) of *M. smegmatis* was compared to its wild-type parent (18) for reversion frequency. This experiment was performed as outlined in Fig. 3 for mc²⁶. The results revealed no significant difference for the *recA* strain.

Stationary-phase hypermutability. Increased frequencies of mutation to streptomycin or rifampin resistance in *M. smegmatis* were noted (Fig. 4) when cells were plated on selective medium late in stationary phase. As confirmation of this hypermutability, a His⁻ auxotroph of *M. smegmatis* (*his5*) was tested for reversion during exponential and stationary phases of growth. The results indicate that reversion to prototrophy reached a frequency as high as 10⁻³ prototroph CFU/total CFU when the cultures in late stationary phase were plated on minimal medium. The mutation responsible for histidine auxotrophy in *M. smegmatis* *his5* was located at codon 380 (Gly to Glu [GGG→GAG]) by sequencing the *hisD* gene (Fig. 1). Eight spontaneous *his5* revertants were selected for sequencing of the *hisD* gene in order to map the location of the mutation. In all cases this was detected at codon 380, and all were single-base reversions of the initial mutation (Glu to Gly [GAG→GGG]).

In order to study the possibility of competition between the

TABLE 2. Reversion of streptomycin and rifampin mutations in *M. smegmatis*

Mutant	Amino acid		Codon alteration	Reversion
	Position	Exchange		
Str ^r				
R43L	43	Lys→Arg	AAG→AGG	AGG→AAG
N43L	43	Lys→Asn	AAG→AAT	AAT→AAG
Rif ^r				
R526H	526	His→Arg	CAC→CGC	CGC→CAC
Y526H	526	His→Tyr	CAC→TAC	TAC→CAC

wild-type and resistant strains during exponential and stationary growth phases, Str^r or Rif^r cultures were mixed with wild-type cultures, dilutions were plated on TSB and TSB containing streptomycin or rifampin, and the ratios of wild-type and Str^r or Rif^r colonies were monitored. Platings at 1, 2, 4, 6, and 8 days of incubation at 30°C indicated no significant difference between the wild-type and resistant strain counts over this period.

Direct PCR analysis of mutation. The enhanced mutation to streptomycin resistance suggested that this event might be detectable at the nucleotide level during growth in liquid culture. To accomplish this, the procedure of EASPCR was used to specifically amplify an *rpsL* DNA fragment of streptomycin-resistant alleles in the bacterial population. We chose to analyze the R43L mutant (AAG→AGG), as this is the most common mutation (found in 7 out of 10 isolates sequenced); the wild-type allele of this mutant can be cleaved by *Mbo*II (for the purpose of EASPCR enrichment). The results (Fig. 2) clearly indicate that the nucleotide sequence changes specific to the mutant allele started to accumulate when *M. smegmatis* cultures entered late stationary phase. This indicates that (as expected) the presence of selecting antibiotic was not required for the generation of resistant mutants. It was not possible to perform a similar analysis with rifampin resistance since there was no convenient restriction enzyme site specific to the wild-type *rpoB* allele that could be used for ASPCR enrichment.

DISCUSSION

Multidrug resistance in *M. tuberculosis* occurs by the accumulation of successive point mutations in various genes affecting antibiotic action (17). We have studied the development of multiple antibiotic resistance in *M. smegmatis* by the isolation of spontaneous mutants resistant to streptomycin and rifampin. According to previous studies by Chakrabarti and Gorini (5, 6), there exists antagonism between *rpsL* and *rpoB* mutations in *E. coli*. These authors showed that paired streptomycin and rifampin resistance mutations lead to a temperature-sensitive phenotype in *E. coli*, and they suggested a possible mechanical coupling between ribosome and RNA polymerase such that certain combinations of *rpsL* and *rpoB* mutations are unable to interact effectively. Our studies suggest that a similar antagonism may exist in *M. smegmatis*. This was concluded on the basis of two observations: (i) when Str^r mutants were isolated from a Rif^r parent, or Rif^r mutants were isolated from an Str^r parent, the parental resistant mutation reverted to wild type at high frequency; and (ii) when Str^r *M. smegmatis* mutants were plated on medium containing selective concentrations of both streptomycin and rifampin, they gave rise to Str^r Rif^r double mutants at a significantly lower frequency than when selection was done on rifampin alone. The same was true when a Rif^r parent was used and Rif^r Str^r double mutants were selected. The mechanism for reversion at such a high frequency is not known. Antagonism between *rpsL* and *rpoB* mutations might provide strong selection, and it is possible that other factors, such as the physiological cost of harboring resistance mutations, could play a role in this process. A recent study of the physiological cost of Rif^r in *M. tuberculosis* indicated that the relative fitness of all but one mutant allele studied was lower than that of the antibiotic-susceptible parent (2). Gene conversion is considered unlikely to have a role, since a *recA* mutant of *M. smegmatis* showed similar reversion of the initial antibiotic resistance phenotype.

Rosenberg et al. (22) proposed a model for adaptive reversion in the *lac* frameshift system where starvation (stress) could stimulate the formation of double-strand breaks in a small

subset of the cells. It is known that in mammalian cells, chromosomal double-strand breaks can induce gene conversion at high frequency (24). We assume that in the cases of double selection for both resistance alleles there may be compensatory mutations that permit coexistence of Str^r and Rif^r in *M. smegmatis*, but this has not been analyzed for mycobacteria. We suggest that the temperature sensitivity in *E. coli* with combined mutations of streptomycin and rifampin resistance, found by Chakrabarti and Gorini (6), might be due to such compensatory mutations. There is ample evidence (1) for the occurrence of compensatory mutations restoring fitness to antibiotic-resistant strains of bacteria. In many cases the compensatory mutation occurs in the same gene as the mutation to resistance or in a gene encoding a related biochemical function.

The fact that reversion of antibiotic resistance occurred at such high frequencies (Table 1), which was confirmed by the EASPCR studies (Fig. 2), suggests that *M. smegmatis* is capable of hypermutation under specific conditions. For example, in the experiment of Table 1, the mutation to Str^r (which occurs coincidentally with reversion of Rif^r to Rif^s) appeared at a frequency as high as 10⁻³ mutant CFU/total CFU. Similar high frequencies of reversion of a histidine auxotroph to prototrophy were also found.

There are several explanations for hypermutability. First, it is possible that *M. smegmatis* is defective in mismatch repair (*M. tuberculosis* has no *mutS* analog) (15), which would lead to an increase in mutation rate. Since it is known that sigma factors (*sigH* and *sigE*) regulate expression of many genes in stationary phase (9), a sigma factor-associated down-regulation or the collapse of an alternative repair system could explain why hypermutation occurs only when cultures enter late stationary phase. Second, there are numerous studies demonstrating the growth-dependent alteration of mutation rates; an example is growth advantage in stationary phase, in which subpopulations of mutant cells may take over stationary-phase cultures (27). However, mixed cultures of antibiotic-sensitive and -resistant strains of *M. smegmatis* gave no evidence of any obvious population takeovers by the mutant strains.

Specific DNA mutases, such as DNA polymerase IV (*dinB*) and DNA polymerase V (*umuCD'*), have been shown to allow higher mutation rates under certain conditions (19). A recent survey of the existence of the DinB- and UmuC-like protein families revealed the presence of similar catalytic domains in more than 30 sequences, including that of *M. tuberculosis* (26). Another possibility is that hypermutation could occur as a small subpopulation of the cells undergo genomewide mutagenesis but do not survive unless a selected (adaptive) mutation is generated (12). Adaptive mutation (4) or stressful-lifestyle-associated mutation (21), which could be induced by selection, stationary phase, or stress, might also explain the hypermutation effects seen in our studies with antibiotic resistance in *M. smegmatis*. In addition, although we found evidence of hypermutation by EASPCR before the cells were exposed to antibiotic selection, we cannot rule out the possibility that both streptomycin and rifampin could have enhanced the selection-induced hypermutable state. In fact, streptomycin is known to be mutagenic (10, 20).

Since the existence of MDRTB poses an increasing challenge in the treatment of tuberculosis, our analyses of Str^r and Rif^r mutants of *M. smegmatis* raise significant questions concerning the genetics of the development of multiple mutations to drug resistance in *M. tuberculosis*. Do antagonistic interactions occur between the point mutations and deletions that lead to resistance to combinations of rifampin, streptomycin, isoniazid, amikacin, and pyrazinamide in *M. tuberculosis*, and if

so, in what manner are they compensated? Detailed comparative analyses of the genome sequences of *M. tuberculosis* and derived MDR strains will be revealing in this respect. We consider it unlikely that the MDR strains will consist simply of successive drug-resistant mutations. Finally, given the fact that *M. tuberculosis* propagates under a variety of stress conditions during its infectious process, it is reasonable to assume that these conditions may lead to hypermutation; such physiological situations will be difficult to study under normal laboratory growth and selection. Considering the number of mutations (up to six) MDRTB strains carry, as well as the fact that some of these mutations being antagonistic will lead to additional compensatory mutations, it is possible that hypermutability is inevitable to the lifestyle of *M. tuberculosis*. It is difficult to reconcile this with the available data which suggest that the average mutation rates for resistance to antibiotics in *M. tuberculosis* were on the order of 10^{-7} or 10^{-8} or even lower (about 10^{-10} for rifampin resistance) (7, 8), although it must be noted that the mutation frequencies reported for *M. tuberculosis* represent mutations per bacterium per generation, whereas our results are presented as the ratios of antibiotic-resistant to -sensitive colonies.

ACKNOWLEDGMENTS

We are grateful for generous financial support from the Canadian Bacterial Diseases Network.

We thank Neil G. Stoker for providing the His⁻ mutant strain of *M. smegmatis*, Karen Lu for expert technical assistance, Fernando de la Cruz for valuable discussions, and George Spiegelman for comments on the manuscript.

REFERENCES

1. Andersson, D. I., and B. R. Levin. 1999. The biological cost of antibiotic resistance. *Curr. Opin. Microbiol.* **2**:489–493.
2. Billington, O. J., T. D. McHugh, and S. H. Gillespie. 1999. Physiological cost of rifampin resistance induced in vitro in *Mycobacterium tuberculosis*. *Antimicrob. Agents Chemother.* **43**:1866–1869.
3. Bloom, B. R., and C. J. L. Murray. 1992. Tuberculosis: commentary on a reemergent killer. *Science* **257**:1055–1064.
4. Cairns, J., J. Overbaugh, and S. Miller. 1988. The origins of mutants. *Nature* **335**:142–145.
5. Chakrabarti, S. L., and L. Gorini. 1975. A link between streptomycin and rifampin mutation. *Proc. Natl. Acad. Sci. USA* **72**:2084–2087.
6. Chakrabarti, S. L., and L. Gorini. 1977. Interaction between mutations of ribosomes and RNA polymerase: a pair of *strA* and *rif* mutants individually temperature-insensitive but temperature-sensitive in combination. *Proc. Natl. Acad. Sci. USA* **74**:1157–1161.
7. David, H. L. 1970. Probability distribution of drug-resistant mutants in unselected populations of *Mycobacterium tuberculosis*. *Appl. Microbiol.* **20**:810–814.
8. David, H. L., and C. M. Newman. 1971. Some observations on the genetics of isoniazid resistance in the tubercle bacilli. *Am. Rev. Respir. Dis.* **104**:508–515.
9. Fernandes, N. D., Q.-L. Wu, D. Kong, X. Puyang, S. Garg, and R. N. Husson. 1999. A mycobacterial extracytoplasmic sigma factor involved in survival following heat shock and oxidative stress. *J. Bacteriol.* **181**:4266–4274.
10. Fernandez, B., F. L. Haas, and O. Wyss. 1953. Induced host-range mutations in bacteriophage. *Proc. Natl. Acad. Sci. USA* **39**:1052–1057.
11. Finken, M., P. Kirschner, A. Meier, A. Wrede, and C. Bottger. 1993. Molecular basis of streptomycin resistance in *Mycobacterium tuberculosis*: alterations of the ribosomal protein S12 gene and point mutations within a functional 16S ribosomal RNA pseudoknot. *Mol. Microbiol.* **9**:1239–1246.
12. Hall, B. G. 1990. Spontaneous point mutations that occur more often when advantageous than when neutral. *Genetics* **126**:5–16.
13. Hinshelwood, S., and N. G. Stoker. 1992. Cloning of mycobacterial histidine synthesis genes by complementation of a *Mycobacterium smegmatis* auxotroph. *Mol. Microbiol.* **6**:2887–2895.
14. McClure, W. R., and C. L. Cech. 1978. On the mechanism of rifampicin inhibition of RNA synthesis. *J. Biol. Chem.* **253**:8949–8956.
15. Mizrahi, V., and S. J. Andersen. 1998. DNA repair in *Mycobacterium tuberculosis*. What have we learnt from the genome sequence? *Mol. Microbiol.* **29**:1331–1339.
16. Morris, S., G. H. Bai, P. Suffys, L. Portillo-Gomez, M. Fairchok, and D. Rouse. 1995. Molecular mechanisms of multiple drug resistance in clinical isolates of *Mycobacterium tuberculosis*. *J. Infect. Dis.* **171**:954–960.
17. Musser, J. M. 1995. Antimicrobial agent resistance in mycobacteria: molecular genetic insights. *Clin. Microbiol. Rev.* **8**:496–514.
18. Papavinasasundaram, K. G., M. J. Colston, and E. O. Davis. 1998. Construction and complementation of a *recA* deletion mutant of *Mycobacterium smegmatis* reveals that the intein in *Mycobacterium tuberculosis recA* does not affect RecA function. *Mol. Microbiol.* **30**:525–534.
19. Radman, M. 1999. Enzymes of evolutionary change. *Nature* **401**:866–869.
20. Ren, L., M. S. Rahman, and M. Z. Humayun. 1999. *Escherichia coli* cells exposed to streptomycin display a mutator phenotype. *J. Bacteriol.* **181**:1043–1044.
21. Rosenberg, S. M. 1994. In pursuit of a molecular mechanism for adaptive mutation. *Genome* **37**:893–899.
22. Rosenberg, S. M., R. S. Harris, and J. Torkelson. 1995. Molecular handles on adaptive mutation. *Mol. Microbiol.* **18**:185–189.
23. Ruusala, T., and G. C. Kurland. 1984. Streptomycin preferentially perturbs ribosomal proofreading. *Mol. Gen. Genet.* **198**:100–104.
24. Taghian, D. G., and J. A. Nickoloff. 1997. Chromosomal double-strand breaks induce gene conversion at high frequency in mammalian cells. *Mol. Cell. Biol.* **17**:6386–6393.
25. Telenti, A., P. Imboden, F. Marchesi, D. Lowrie, S. Cole, M. J. Colston, L. Matter, K. Schopfer, and T. Bodmer. 1993. Detection of rifampicin-resistance mutations in *Mycobacterium tuberculosis*. *Lancet* **341**:647–650.
26. Wagner, J., P. Gruz, S. R. Kim, M. Yamada, K. Matsui, R. P. Fuchs, and T. Nohmi. 1999. The *dinB* gene encodes a novel *E. coli* DNA polymerase, DNA pol IV, involved in mutagenesis. *Mol. Cell* **4**:281–286.
27. Zambrano, M. M., and R. Kolter. 1996. GASping for life in stationary phase. *Cell* **86**:181–184.